fig1

Non-invasive assessment in MASLD: from biomarker discovery to clinical pathway integration

Figure 1. Non-invasive assessment across the MASLD disease continuum. The figure shows the limitations of liver biopsy, the roles of established and emerging tools in a stepwise clinical pathway, and key barriers and future directions for clinical translation. The pathway is conceptual. APRI: Aspartate aminotransferase-to-platelet ratio index; CT: computed tomography; cT1: corrected T1; ELF: enhanced liver fibrosis; FIB-4: fibrosis-4 index; HCC: hepatocellular carcinoma; MASLD: metabolic dysfunction-associated steatotic liver disease; MASH: metabolic dysfunction-associated steatohepatitis; MPF: macromolecular proton fraction; MRE: magnetic resonance elastography; MRI: magnetic resonance imaging; MRI-PDFF: MRI-derived proton density fat fraction; NFS: nonalcoholic fatty liver disease fibrosis score; SWE: shear wave elastography; T1ρ: spin-lattice relaxation time in the rotating frame; US: ultrasound; VCTE: vibration-controlled transient elastography.